New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders

5-HT4 receptor agonists: similar but not the same

(2010) J. H. De Maeyer et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Selective desensitization of the 5-HT4receptor-mediated response in pig atrium but not in stomach

(2009) JH De Maeyer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study

(2009) m. camilleri et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Translating 5-HT4receptor pharmacology

(2009) g. j. sanger   NEUROGASTROENTEROLOGY AND MOTILITY

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study

(2008) E. M. M. QUIGLEY et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

(2008) J Tack et al.   GUT

The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity

(2008) D. T. Beattie et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Morphometric evaluation of oesophageal wall in patients with nutcracker oesophagus and ineffective oesophageal motility

(2008) h. s. kim et al.   NEUROGASTROENTEROLOGY AND MOTILITY

A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation

(2008) Michael Camilleri et al.   NEW ENGLAND JOURNAL OF MEDICINE